
Please try another search
Solasia Pharma K.K. engages in the development and marketing of oncology drugs in Japan and other Asian countries. The company offers Episil, an oral liquid for oral mucositis/stomatitis; and DARVIAS, an antineoplastic agent injection for relapsed or refractory peripheral T-cell lymphoma. It also develops Sancuso for chemotherapy induced nausea and vomiting; SP-04, which is in preclinical trial development to treat chemotherapy peripheral neuropathy; and SP-05 for the treatment of colorectal cancer. The company was founded in 2006 and is based in Tokyo, Japan.
Name | Age | Since | Title |
---|---|---|---|
Susumu Araki | 73 | 2019 | Full-time Outside Audit & Supervisory Board Member |
Yoshihiro Arai | 65 | 2013 | President, CEO & Representative Director |
Jiro Mizukawa | 73 | 2020 | Independent Outside Director |
Stanley Lau | 71 | 2014 | Independent Outside Director |
Norikazu Eiki | 77 | 2016 | Independent Outside Director |
Toshio Miyashita | 58 | 2014 | CFO, Head of Management Headquarters & Director |
Nagisa Kawaida | 36 | 2024 | Outside Audit & Supervisory Board Member |
Eisaku Nakamura | 64 | 2025 | External Corporate Auditor |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review